Inventor · disambiguated record
David B. Rozema
Also filed as: ROZEMA DAVID · ROZEMA DAVID B
82 granted patents·57 pending applications·1,648 citations·filing 1994–2025
99Inventor score
Files withEMPIRICO INC36ARROWHEAD PHARMACEUTICALS INC24MIRUS BIO CORP13ROZEMA DAVID B13ARROWHEAD MADISON INC11
Top patents by PatentIndex Score
139 records- 0199US8541548B2Compounds and methods for reversible modification of biologically active moleculesROZEMA DAVID B·Filed 2008·Granted Sep 24, 2013·85 cites·10 claims
- 0299US8313772B2Compositions for targeted delivery of siRNAROZEMA DAVID B·Filed 2011·Granted Nov 20, 2012·159 cites·25 claims
- 0399US7098032B2Compositions and methods for drug delivery using pH sensitive moleculesMIRUS BIO CORP·Filed 2005·Granted Aug 29, 2006·114 cites·32 claims
- 0498US8658211B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2012·Granted Feb 25, 2014·71 cites·23 claims
- 0598US8501930B2Peptide-based in vivo siRNA delivery systemROZEMA DAVID B·Filed 2011·Granted Aug 6, 2013·180 cites·18 claims
- 0698US8137695B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2007·Granted Mar 20, 2012·138 cites·27 claims
- 0797US7138382B2Compositions and methods for drug delivery using pH sensitive moleculesMIRUS BIO CORP·Filed 2003·Granted Nov 21, 2006·83 cites·12 claims
- 0896US11879125B2GalNAc compositions for improving siRNA bioavailabilityEMPIRICO INC·Filed 2023·Granted Jan 23, 2024·3 cites·20 claims
- 0996US11116778B2Prodrugs of ALOX-15 inhibitors and methods of using the sameEMPIRICO INC·Filed 2020·Granted Sep 14, 2021·9 cites·9 claims
- 1096US10130651B2RNAi Therapy for Hepatitis B Virus InfectionARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Nov 20, 2018·22 cites·18 claims
- 1195US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
- 1295US9796756B2Galactose cluster-pharmacokinetic modulator targeting moiety for siRNAARROWHEAD MADISON INC·Filed 2015·Granted Oct 24, 2017·24 cites·20 claims
- 1395US8802773B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2013·Granted Aug 12, 2014·12 cites·22 claims
- 1495US8426554B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2011·Granted Apr 23, 2013·47 cites·14 claims
- 1595US6919091B2Compositions and methods for drug delivery using pH sensitive moleculesMIRUS CORP·Filed 2002·Granted Jul 19, 2005·39 cites·15 claims
- 1695US6740643B2Compositions and methods for drug delivery using amphiphile binding moleculesMIRUS CORP·Filed 2000·Granted May 25, 2004·68 cites·15 claims
- 1794US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 1894US11377658B2Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseasesEMPIRICO INC·Filed 2021·Granted Jul 5, 2022·2 cites·20 claims
- 1993US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
- 2093US7482160B2Process of making a compound by forming a polymer from a template drugROCHE MADISON INC·Filed 2005·Granted Jan 27, 2009·11 cites·17 claims
- 2193US6630351B1Compositions and methods for drug delivery using pH sensitive moleculesMIRUS CORP·Filed 2000·Granted Oct 7, 2003·61 cites·12 claims
- 2292US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 2392US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 2492US10246709B2Targeting ligands for therapeutic compoundsARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·10 cites·27 claims
- 2592US7033607B2pH-titratable polyampholytes for delivering polyions to a cellMIRUS BIO CORP·Filed 2002·Granted Apr 25, 2006·34 cites·20 claims
- 2690US10941404B2Treatment of angiopoietin like 7 (ANGPTL7) related diseasesEMPIRICO INC·Filed 2020·Granted Mar 9, 2021·2 cites·20 claims
- 2790US7442764B2Reversible modification of amine-containing compoundsMIRNS BIO CORP·Filed 2005·Granted Oct 28, 2008·10 cites·20 claims
- 2890US7348453B2Labile linkage for compound delivery to a cellMIRUS BIO CORP·Filed 2004·Granted Mar 25, 2008·24 cites·7 claims
- 2990US7019113B2Reversible modification of membrane interactionMIRUS BIO CORP·Filed 2003·Granted Mar 28, 2006·38 cites·18 claims
- 3089US10806750B2RNAi therapy for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·3 cites·9 claims
- 3189US7098030B2Polyampholytes for delivering polyions to a cellMIRUS BIO CORP·Filed 2004·Granted Aug 29, 2006·25 cites·20 claims
- 3288US10131911B2Post-transcriptionally chemically modified double strand RNAsnanoSUR LLC·Filed 2017·Granted Nov 20, 2018·4 cites·9 claims
- 3388US9345775B2Compositions for targeted delivery of siRNAARROWHEAD MADISON INC·Filed 2015·Granted May 24, 2016·5 cites·27 claims
- 3488US7087770B2Compound containing a labile disulfide bondMIRUS BIO CORP·Filed 2001·Granted Aug 8, 2006·20 cites·7 claims
- 3588US6379966B2Intravascular delivery of non-viral nucleic acidMIRUS CORP·Filed 1999·Granted Apr 30, 2002·71 cites·14 claims
- 3687US7094605B2Formation of polyampholytes in the presence of a polyionMIRUS BIO CORP·Filed 2005·Granted Aug 22, 2006·6 cites·19 claims
- 3787US2025243485A1Targeting Ligands For Therapeutic CompoundsARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3886US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 3986US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 4086US9011919B2Compositions for targeted delivery of siRNAROZEMA DAVID B·Filed 2012·Granted Apr 21, 2015·7 cites·22 claims
- 4186US6897068B2Polynucleotide complex deliveryMIRUS BIO CORP·Filed 2002·Granted May 24, 2005·18 cites·15 claims
- 4286US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4385US11174480B2Post-transcriptionally chemically modified double strand RNAsnanoSUR LLC·Filed 2018·Granted Nov 16, 2021·1 cites·11 claims
- 4485US10640769B2Post-transcriptionally chemically modified double strand RNAsnanoSUR LLC·Filed 2018·Granted May 5, 2020·2 cites·10 claims
- 4585US9487556B2Polyconjugates for delivery of RNAi triggers to tumor cells in vivoARROWHEAD MADISON INC·Filed 2014·Granted Nov 8, 2016·6 cites·18 claims
- 4685US8211468B2Endosomolytic polymersROZEMA DAVID B·Filed 2006·Granted Jul 3, 2012·5 cites·2 claims
- 4785US8008355B2Endosomolytic poly(vinyl ether) polymersROCHE MADISON INC·Filed 2008·Granted Aug 30, 2011·5 cites·14 claims
- 4885US7816337B2Reversible attachment of a membrane active polymer to a polynucleotideROCHE MADISON INC·Filed 2004·Granted Oct 19, 2010·12 cites·13 claims
- 4985US7682626B2Polyvinylethers for delivery of polynucleotides to mammalian cellsROCHE MADISON INC·Filed 2004·Granted Mar 23, 2010·10 cites·15 claims
- 5085US7208314B2Compositions and methods for drug delivery using pH sensitive moleculesMIRUS BIO CORP·Filed 2002·Granted Apr 24, 2007·16 cites·8 claims
Showing the top 50 of 139 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David B. Rozema files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →